CADM1 inhibits squamous cell carcinoma progression by reducing STAT3 activity

Related Experiment Video

Updated: Mar 23, 2026

Multidimensional Coculture System to Model Lung Squamous Carcinoma Progression
07:53

Multidimensional Coculture System to Model Lung Squamous Carcinoma Progression

Published on: March 17, 2020

7.8K

Sabari Vallath1, Elizabeth K Sage1, Krishna K Kolluri1

  • 1Lungs for Living Research Centre, University College London, UK.

Scientific Reports
|April 2, 2016
PubMed

Insights

The tumor suppressor Cell adhesion molecule 1 (CADM1) inhibits squamous cell carcinoma (SqCC) progression by disrupting STAT3 signaling. Restoring CADM1 or inhibiting JAK/STAT pathways with ruxolitinib halts SqCC growth and metastasis.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Genetics

Background:

  • Squamous cell carcinomas (SqCCs) are a significant cause of cancer mortality, yet the molecular mechanisms driving their progression are not fully understood.
  • Cell adhesion molecule 1 (CADM1) is a known tumor suppressor, but its specific role in SqCC pathogenesis requires further elucidation.

Purpose of the Study:

  • To investigate the function of the tumor suppressor CADM1 in regulating SqCC proliferation and invasion.
  • To identify the molecular pathways through which CADM1 exerts its anti-cancer effects in SqCC.
  • To explore the therapeutic potential of targeting the CADM1 pathway in SqCC treatment.

Main Methods:

  • Gene transduction techniques were employed to manipulate CADM1 expression in SqCC models.
  • Human tumor xenograft assays were utilized to assess the in vivo effects of CADM1 on tumor growth and metastasis.
  • Biochemical assays were performed to analyze protein complex formation and downstream signaling pathways, including STAT3 activity.

Main Results:

  • CADM1 was found to inhibit SqCC proliferation and invasion, critical processes in cancer progression.
  • The extracellular domain of CADM1 mediates its tumor-suppressive function by forming a complex with HER2 and integrin α6β4.
  • This complex formation disrupts downstream STAT3 signaling, thereby inhibiting SqCC growth and metastasis.
  • Treatment of CADM1-deficient tumors with the JAK/STAT inhibitor ruxolitinib effectively mimicked the effects of CADM1 restoration, suppressing tumor growth and metastasis.

Conclusions:

  • CADM1 acts as a crucial tumor suppressor in SqCC by inhibiting proliferation and invasion through a novel mechanism involving HER2 and integrin α6β4 complex formation.
  • Disruption of STAT3 signaling by CADM1 is a key pathway by which it controls SqCC progression.
  • Loss of CADM1 expression in tumors can identify patients who may benefit from JAK/STAT targeted therapies, such as ruxolitinib.

More Related Videos

An Immunofluorescent Method for Characterization of Barrett’s Esophagus Cells08:54

An Immunofluorescent Method for Characterization of Barrett’s Esophagus Cells

Published on: July 20, 2014

14.5K
Quantitative PCR-based Assay to Measure Sonic Hedgehog Signaling in Cellular Model of Ciliogenesis07:26

Quantitative PCR-based Assay to Measure Sonic Hedgehog Signaling in Cellular Model of Ciliogenesis

Published on: January 31, 2025

1.2K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.2K
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

5.6K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.4K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
13.8K
Cadherins in Tissue Organization01:19

Cadherins in Tissue Organization

The cadherins are a superfamily of cell adhesion molecules comprising over 180 variants, with specific tissues expressing a particular combination of cadherin types. Cadherins generally exhibit homophilic binding; i.e., cadherins on one cell bind to cadherins of the same or closely related type on another cell. Thus, cells of the same type have a specific affinity to bind to each other and sort themselves into clusters to form tissues.
Cell Sorting During Development
Cell sorting plays an...
4.5K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.0K